Cargando…

The use status of anticoagulation drugs for inpatients with nonvalvular atrial fibrillation in Southwest China

BACKGROUND: Oral anticoagulants (OACs) are effective for the prophylaxis of stroke in patients with atrial fibrillation (AF). This cross-sectional study aimed to investigate the status of anticoagulation treatment for hospitalized AF patients in Southwest China. METHODS: A total of 4760 hospitalized...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Huan Jie, Ouyang, Shu Kun, Zhao, Yue, Lu, Kai, Luo, Su Xin, Xiao, Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345993/
https://www.ncbi.nlm.nih.gov/pubmed/28293117
http://dx.doi.org/10.2147/IJGM.S128047
_version_ 1782513817601703936
author Zheng, Huan Jie
Ouyang, Shu Kun
Zhao, Yue
Lu, Kai
Luo, Su Xin
Xiao, Hua
author_facet Zheng, Huan Jie
Ouyang, Shu Kun
Zhao, Yue
Lu, Kai
Luo, Su Xin
Xiao, Hua
author_sort Zheng, Huan Jie
collection PubMed
description BACKGROUND: Oral anticoagulants (OACs) are effective for the prophylaxis of stroke in patients with atrial fibrillation (AF). This cross-sectional study aimed to investigate the status of anticoagulation treatment for hospitalized AF patients in Southwest China. METHODS: A total of 4760 hospitalized patients with AF were enrolled from 21 hospitals in Chongqing city from January 1 to December 31, 2013. RESULTS: Among the enrolled patients, 3785 were diagnosed with nonvalvular AF. These patients had a mean age of 74.4±10.1 years. The mean CHADS(2) score of all subjects was 2.60±1.34, and 80.7% of the patients had CHADS(2) ≥2. The use rate of OACs was only 11.5% for patients with a high risk for stroke (CHADS(2) ≥2) and was much lower in patients from the second-level hospitals than in patients from the third-level hospitals (5.8% vs. 16.9%, P<0.001). The leading reason for the underuse of OACs in high-risk patients was physician’s nonfeasance. CONCLUSION: This study demonstrated that the underuse of anticoagulation therapy in hospitalized patients with nonvalvular AF was particularly serious in Southwest China, especially in the second-level hospitals. Urgent and effective measures are desperately needed to improve this alarming situation in China.
format Online
Article
Text
id pubmed-5345993
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-53459932017-03-14 The use status of anticoagulation drugs for inpatients with nonvalvular atrial fibrillation in Southwest China Zheng, Huan Jie Ouyang, Shu Kun Zhao, Yue Lu, Kai Luo, Su Xin Xiao, Hua Int J Gen Med Original Research BACKGROUND: Oral anticoagulants (OACs) are effective for the prophylaxis of stroke in patients with atrial fibrillation (AF). This cross-sectional study aimed to investigate the status of anticoagulation treatment for hospitalized AF patients in Southwest China. METHODS: A total of 4760 hospitalized patients with AF were enrolled from 21 hospitals in Chongqing city from January 1 to December 31, 2013. RESULTS: Among the enrolled patients, 3785 were diagnosed with nonvalvular AF. These patients had a mean age of 74.4±10.1 years. The mean CHADS(2) score of all subjects was 2.60±1.34, and 80.7% of the patients had CHADS(2) ≥2. The use rate of OACs was only 11.5% for patients with a high risk for stroke (CHADS(2) ≥2) and was much lower in patients from the second-level hospitals than in patients from the third-level hospitals (5.8% vs. 16.9%, P<0.001). The leading reason for the underuse of OACs in high-risk patients was physician’s nonfeasance. CONCLUSION: This study demonstrated that the underuse of anticoagulation therapy in hospitalized patients with nonvalvular AF was particularly serious in Southwest China, especially in the second-level hospitals. Urgent and effective measures are desperately needed to improve this alarming situation in China. Dove Medical Press 2017-03-03 /pmc/articles/PMC5345993/ /pubmed/28293117 http://dx.doi.org/10.2147/IJGM.S128047 Text en © 2017 Zheng et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Zheng, Huan Jie
Ouyang, Shu Kun
Zhao, Yue
Lu, Kai
Luo, Su Xin
Xiao, Hua
The use status of anticoagulation drugs for inpatients with nonvalvular atrial fibrillation in Southwest China
title The use status of anticoagulation drugs for inpatients with nonvalvular atrial fibrillation in Southwest China
title_full The use status of anticoagulation drugs for inpatients with nonvalvular atrial fibrillation in Southwest China
title_fullStr The use status of anticoagulation drugs for inpatients with nonvalvular atrial fibrillation in Southwest China
title_full_unstemmed The use status of anticoagulation drugs for inpatients with nonvalvular atrial fibrillation in Southwest China
title_short The use status of anticoagulation drugs for inpatients with nonvalvular atrial fibrillation in Southwest China
title_sort use status of anticoagulation drugs for inpatients with nonvalvular atrial fibrillation in southwest china
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345993/
https://www.ncbi.nlm.nih.gov/pubmed/28293117
http://dx.doi.org/10.2147/IJGM.S128047
work_keys_str_mv AT zhenghuanjie theusestatusofanticoagulationdrugsforinpatientswithnonvalvularatrialfibrillationinsouthwestchina
AT ouyangshukun theusestatusofanticoagulationdrugsforinpatientswithnonvalvularatrialfibrillationinsouthwestchina
AT zhaoyue theusestatusofanticoagulationdrugsforinpatientswithnonvalvularatrialfibrillationinsouthwestchina
AT lukai theusestatusofanticoagulationdrugsforinpatientswithnonvalvularatrialfibrillationinsouthwestchina
AT luosuxin theusestatusofanticoagulationdrugsforinpatientswithnonvalvularatrialfibrillationinsouthwestchina
AT xiaohua theusestatusofanticoagulationdrugsforinpatientswithnonvalvularatrialfibrillationinsouthwestchina
AT zhenghuanjie usestatusofanticoagulationdrugsforinpatientswithnonvalvularatrialfibrillationinsouthwestchina
AT ouyangshukun usestatusofanticoagulationdrugsforinpatientswithnonvalvularatrialfibrillationinsouthwestchina
AT zhaoyue usestatusofanticoagulationdrugsforinpatientswithnonvalvularatrialfibrillationinsouthwestchina
AT lukai usestatusofanticoagulationdrugsforinpatientswithnonvalvularatrialfibrillationinsouthwestchina
AT luosuxin usestatusofanticoagulationdrugsforinpatientswithnonvalvularatrialfibrillationinsouthwestchina
AT xiaohua usestatusofanticoagulationdrugsforinpatientswithnonvalvularatrialfibrillationinsouthwestchina